Novel immunoassay for the measurement of complexed prostate-specific antigen in serum

Clinical Chemistry

Volumn 44, Issue 6, 1998, Pages 1216-1223

  Allard, W Jeffrey ^a   Zhou, Zeqi ^a   Yeung, Kwok K ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; AUTOANALYSIS; AUTOANALYZER; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN DETERMINATION;

EID: 0031800404     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.6.1216     Document Type: Article

References (32)

1. Watt KWK, Lee P-J, Timkulu TM, Chan W-P, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986;83:3166-70.
2. Melegos DN, Diamandis EP. Diagnostic value of molecular forms of prostate-specific antigen for female breast cancer [Review]. Clin Biochem 1996;29:193-200.
3. Kamoshida S, Tsutsumi Y. Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. Hum Pathol 1990;21:1108-12.
4. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Eng J Med 1987;317:909-16.
5. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Eng J Med 1991;324:1156-61.
6. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994 [Review]. J Urol 1994;152:1358-68.
7. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994;151:1283-90.
8. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostate carcinoma with prostate specific antigen. J Urol 1992;147:841-5.
9. Ellis WJ, Chetner MP, Preston SD, Brawer MK. Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 1994;152:1520-5.
10. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH. Prostate specific antigen density: a means of distinguishing prostatic hypertrophy and prostate cancer. J Urol 1992; 147:815-6.
11. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
12. Oesterling JE, Jacobsen SJ, Cooner WH. The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol 1995;153:1160-3.
13. Stenman U-H, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and α-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51: 222-6.
14. Lilja H, Christensson A, Dahlen U, Matikainen M-T, Nilsson O, Pettersson, Lovgren T. Prostate-specific antigen in serum occurs predominantly in complex with α-1-antichymotrypsin. Clin Chem 1991;37:1618-25.
15. Lilja H, Cockett ATK, Abrahamsson P-A. Prostate specific antigen predominantly forms a complex with α-1-antichymotrypsin in blood. Cancer 1992;70:230-4.
16. Pettersson K, Piironen T, Seppala M, Liukkonen L, Christensson A, Matikainen M-T, et al. Free and complexed prostate-specific antigen: in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-α-1-antichymotrypsin complex. Clin Chem 1995; 41:1480-8.
17. Chan DW, Kelley CA, Partin AW. PSA-ACT immunoassay. problems and solutions [Abstract]. Clin Chem 1996;42:S255.
18. Zhang P, Wu JT. Development of an immunoassay specific for the PSA-ACT complex in serum without interference of non-specific adsorption [Abstract]. Clin Chem 1997;43:S236.
19. Chan DW, Sokoll LJ. Prostate specific antigen: update 1997 [Review]. J Int Fed Clin Chem 1997;9:120-5.
20. Wang TJ, Linton HJ, Payne J, Liu R-S, Kuus-Reichel K, Rittenhouse HG, et al. Development of monoclonal antibodies specific for the PSA-ACT complex and their incorporation into an immunoassay [Abstract]. Clin Chem 1997;43:S225.
21. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen M-T, Cockett ATK, et al. Serum prostate specific antigen complexed to α-1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
22. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB. Evaluation of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
23. Zhou Z, Armstrong EG, Belenky A, Freeman JV, Yeung KK. Equivalent recognition of free and ACT-complexed PSA in a monoclonal polyclonal sandwich assay is conferred by binding specificity of the monoclonal antibody. J Clin Lab Anal (in press).
24. Zhou Z, Ng PC, Very DL, Allard WJ, Yeung KK. Technicon Immuno 1® PSA Assay measures both free and α-1-antichymotrypsin-complexed prostate-specific antigen on an equimolar basis. J Clin Lab Anal 1996;10:155-9.
25. Zhou Z, Barnett TR, Very DL, Ng PC, Brini CM, Davis G, Belenky A, Allard WJ, Yeung KK. Expression of human recombinant prostate specific antigen and specificity analysis of a panel of fifty-three PSA-specific antibodies to native and recombinant PSA. Tumor Biol (in press).
26. Wang TJ, Linton HJ, Payne J, Rittenhouse HG, Wolfert RL, Chan DW, et al. Clinical utility of a complexed PSA immunoassay with a specific monoclonal antibody to PSA-ACT [Abstract]. J Urol 1997;157:147.
27. Leinonen J, Lovgren T, Vornanen T, Stenman U-H. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with α-1-antichymotrypsin. Clin Chem 1993;39:2098-103.
28. Bjork T, Piironen T, Pettersson K, Lovgren T, Stenman U-H, Oesterling JE, et al. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology 1996;48:882-8.
29. Bangma CH, Rietbergen JBW, Kranse R, Blijenberg BG, Pettersson, Schroder FH. The free-to-total prostate specific antigen ration improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol 1997;157: 2191-6.
30. Vashi AR, Wojno KJ, Henricks W, England BA, Vessella RL, Lange PH, et al. Determination of the "reflex range" and appropriate cutpoints for percent free prostate specific antigen in 413 men referred for prostatic evaluation using the AxSym system. Urology 1997;49:19-27.
31. Junker R, Brandt B, Zechel C, Assmann G. Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays. Clin Chem 1997;43:1588-94.
32. Wang TJ, Hill TM, Sokoloff RL, Frankenne F, Rittenhouse HG, Wolfert RL. Dual monoclonal antibody assay for free prostate-specific antigen. Prostate 1996;28:10-6.